NICE

Showing 15 posts of 868 posts found.

ABPI

ABPI warns of postcode prescribing

January 21, 2011
Sales and Marketing ABPI, Cancer Drugs Fund, NICE, cancer drug prescribing, postcode prescribing

The ABPI has said the government’s forthcoming Cancer Drugs Fund could increase the problems of postcode prescribing. The UK industry …

Health Bill continues fast pace of NHS reform

January 20, 2011
Sales and Marketing GP consortia, NHS, NHS Commissioning Board, NHS reforms, NICE, QALY

The government has outlined its draft Health and Social Care Bill, making some minor concessions to critics but promising no …

Leukaemia drug fast-tracked by NICE

January 6, 2011
Sales and Marketing Bendamustine, Levact, NICE, Napp, chronic lymphocytic leukaemia, leukaemia

A treatment for patients with the most common form of leukaemia has been fast tracked by NICE because of strong …

NICE’s public health role reduced

January 4, 2011
NHS, NHS reforms, NICE, public health, quality standards

NICE’s public health remit has been slimmed down as part of the government’s reforms with the removal of six areas …

GSK’s patient access scheme for Votrient sways NICE

December 24, 2010
Sales and Marketing GSK, GlaxoSmithKline, NICE, Votrient, pazopanib, rcc, renal cell carcinoma

NICE has recommended GlaxoSmithKline’s kidney cancer drug Votrient in final draft guidance after the pharma company offered to implement a …

Avastin packs

NICE no for Avastin in breast cancer

December 8, 2010
Sales and Marketing NICE, Roche, avastin, bevacizumab, breast cancer, health technology assessment, hta

NICE has refused to back Roche’s Avastin for use in breast cancer patients citing the blockbuster drug’s high cost and …

Roche's MabThera

NICE recommends MabThera for non-Hodgkin’s lymphoma

December 6, 2010
Sales and Marketing MabThera, NICE, Rituxan, Roche, non-Hodgkin’s lymphoma, rituximab

NICE has given a preliminary green-light to Roche’s MabThera for use as a maintenance therapy for non-Hodgkin’s lymphoma. The Institute’s …

Change is needed, concedes NICE chief, but defends record

November 30, 2010
Sales and Marketing Andrew Dillon, NHS reform, NICE, cost-effectiveness, health technology assessment, hta, value-based pricing

The chief executive of NICE acknowledges changes are needed in how drugs are assessed in the UK – including more …

Novartis’ Afinitor (everolimus)

Novartis fails to sway NICE with Afinitor deal

November 26, 2010
Sales and Marketing Afinitor, Kidney cancer, NICE, Novartis, advanced renal cell carcinoma, everolimus

Novartis has failed to convince NICE that its revised patient access scheme for Afinitor would make the kidney cancer drug …

Tarceva tablet

Roche set to challenge NICE Tarceva decision

November 25, 2010
Sales and Marketing NICE, Roche, Roche UK, Tarceva, erlotinib, lung cancer

NICE has again rejected Roche’s lung cancer drug Tarceva in its second round of draft guidance. Tarceva (erlotinib) was being …

NICE recommends Herceptin for gastric cancer, blocks high dose Glivec

November 24, 2010
Sales and Marketing Cancer, GIST, Glivec, HER2, Herceptin, NICE, gastric cancer

NICE has recommended Roche’s cancer drug Herceptin for patients with HER2 metastatic gastric cancer. NICE was initially minded not to …

Irish cost-effectiveness guidelines published

November 15, 2010
Sales and Marketing Dr Mairin Ryan, Economic Evaluation of Health Technologies, HIQA, Health Information and Quality Authority, IPHA, Ireland, Irish Pharmaceutical Healthcare Association, NICE, hta

The Irish government has published new health technology assessment guidelines to help decision-makers estimate the cost-effectiveness of medical treatments. The …

Blog footer

Digital Pharma: Pfizer and Boehringer’s online COPD awareness

November 12, 2010
Medical Communications Boehringer Ingelheim, COPD, Digital Pharma blog, Managing COPD, NICE, Pfizer, Spiriva, chronic obstructive pulmonary disease

Pfizer and Boehringer Ingelheim have launched an online campaign to publicise the latest NICE guidelines on COPD to healthcare professionals …

Avastin packs

NICE stands firm on Avastin rejection

November 12, 2010
Sales and Marketing NICE, Roche, avastin, bevacizumab, colon cancer, metastatic colorectal cancer, patient access scheme

NICE has refused to recommend Roche’s blockbuster cancer drug Avastin for the treatment of metastatic colorectal cancer in its final …

NICE limits access to cancer drugs, study confirms

November 10, 2010
Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Cancer Drugs Fund, IPSOR, Maximilian Lebmeier, NICE, hta

NICE became more restrictive in its assessment of new cancer drugs between 2007 and 2009, a new report suggests. The …

The Gateway to Local Adoption Series

Latest content